Clinical Trial · NCT07238322

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Overview

This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicion of progression/recurrence on magnetic resonance imaging (MRI).

Sponsor

Telix Pharmaceuticals

ClinicalTrials.gov

NCT07238322

Drug / Compound

FET

Isotope(s):

Target(s):

Amino Acid Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

Underwent \[18F\]FET PET imaging as part of routine clinical care after completion of primary treatment (surgery, radiation therapy, and/or chemotherapy).
Evidence of radiographic suspicion of recurrence or progression on MRI at the time of \[18F\]FET PET imaging.

Exclusion

Any institutional or regulatory requirement that precludes data sharing or inclusion in retrospective research studies.
Did not undergo \[18F\]FET PET imaging as part of routine clinical care.

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…